---
title: "BIOHEART-B published IBERIS-HTN research results in CIRCULATION"
description: "BIOHEART-B announced that the research results of Iberis-HTN have been published in \"Circulation.\" The study evaluated the safety and efficacy of a novel multi-electrode radiofrequency renal denervati"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/220941783.md"
published_at: "2024-11-28T14:05:03.000Z"
---

# BIOHEART-B published IBERIS-HTN research results in CIRCULATION

> BIOHEART-B announced that the research results of Iberis-HTN have been published in "Circulation." The study evaluated the safety and efficacy of a novel multi-electrode radiofrequency renal denervation system in Chinese patients with hypertension. The results showed that RDN is safe in patients whose hypertension remains uncontrolled after standardized triple drug therapy and can effectively reduce both ambulatory blood pressure and office blood pressure. The company's CEO, Wang Li, stated that they look forward to providing safer and more effective renal sympathetic denervation treatments for patients worldwide

According to the Zhitong Finance APP, BIOHEART-B (02185) announced that the results of the Iberis-HTN study, titled "Efficacy and safety of catheter-based radiofrequency renal denervation in Chinese patients with uncontrolled hypertension: the randomized, sham-controlled, multi-center Iberis-HTN trial," have been published in Circulation. The Iberis-HTN study is a key trial for our RDN product, the Iberis renal nerve ablation system, conducted in China.

Renal nerve denervation (RDN) can reduce blood pressure in patients with hypertension, both with and without drug treatment. Iberis-HTN is a sham-controlled trial conducted in China aimed at assessing the safety and efficacy of a novel multi-electrode radiofrequency RDN catheter system in patients whose hypertension remains uncontrolled after standardized triple drug therapy. This study shows that RDN is safe in this trial involving Chinese patients whose hypertension remains uncontrolled after standardized triple drug therapy, and it can reduce ambulatory blood pressure and office blood pressure compared to the sham control group over a period of 6 months.

Professor Jiang Xiongjing and Professor Felix Mahfoud made equal contributions to this publication and are co-first authors, while Academician Gao Runlin is the corresponding author.

The company's founder and CEO, Wang Li, stated: "We are pleased to see our Iberis-HTN trial results published in Circulation. This is also our first trial published that includes the renal nerve ablation procedure performed via the transradial approach (TRA). TRA makes RDN safer, more effective, and more cost-effective. Our ultimate goal is to provide outpatient treatment for renal sympathetic nerve ablation to patients worldwide."

### Related Stocks

- [02185.HK - BIOHEART-B](https://longbridge.com/en/quote/02185.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Guotai Haitong Sticks to Its Buy Rating for Shenzhen Edge Medical Co., Ltd. Class H (2675) | Guotai Haitong analyst maintained a Buy rating on Shenzhen Edge Medical Co., Ltd. Class H yesterday and set a price targ | [Link](https://longbridge.com/en/news/275997117.md) |
| 23:43 ETDie innovativen Sicherheits- und hocheffizienten Antriebsstränge von GAC finden weltweite Anerkennung | GAC is gaining global recognition for its innovative and efficient drivetrains amidst the rapidly changing automotive in | [Link](https://longbridge.com/en/news/275994919.md) |
| B Investments Studying Egp 2–3 Bln In Potential Investments Over Two Years | B INVESTMENTS HOLDING SAE :CURRENTLY STUDYING INVESTMENT OPPORTUNITIES IN RANGE OF EGP 2-3 BILLION OVER NEXT TWO YEARSIN | [Link](https://longbridge.com/en/news/275720724.md) |
| Euronext Oslo Børs - Decision on admission to trading - Pelagic Credit Plc. | Euronext Oslo Børs has approved the admission of Pelagic Credit Plc. to trading on Euronext Growth Oslo. The company is  | [Link](https://longbridge.com/en/news/276064735.md) |
| Impressive Earnings May Not Tell The Whole Story For Heba Fastighets (STO:HEBA B) | Heba Fastighets AB (STO:HEBA B) reported strong profits, but concerns arise from a kr190m gain attributed to unusual ite | [Link](https://longbridge.com/en/news/275999346.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.